Hypertrophy and hyperplasia of alveolar type II cells in response to silica and other pulmonary toxicants

Environmental Health Perspectives
B E Miller, G E Hook

Abstract

Alveolar Type II cells serve two major functions in the lung, both of which are essential for the preservation of normal lung function. First, Type II cells synthesize and secrete pulmonary surfactant, and second, they function as progenitor cells for maintaining the alveolar epithelium. The Type II cell population of the lung is quite sensitive to the deposition of toxicants in the distal lung, responding in two principal ways. Damage to the Type I epithelium stimulates Type II cells to proliferate and subsequently differentiate to replace the injured Type I cells. Second, a portion of the Type II cell population may become hypertrophic. Both of these events are frequent findings in the diseased or damaged lung. The Type II cell changes are often associated with increases in surfactant pools. In those cases where ultrastructural characteristics of hypertrophic Type II cells were examined, the appearance of these cells was consistent with that of an activated cell type. Alterations in the lamellar body compartment are a common finding in hypertrophic Type II cells, with increases in both lamellar body size and number. It is likely that the hypertrophic, or activated, Type II cells account for the increased levels of surfactant ...Continue Reading

References

Feb 1, 1975·Experimental and Molecular Pathology·M J EvansG Freeman
Jul 1, 1978·Environmental Research·S GaborD Andrasoni
Feb 7, 1978·Biochemistry·G E Hook
Dec 1, 1975·The Biochemical Journal·J L HarwoodR Richards
May 1, 1987·The Biochemical Journal·R W LewisR J Richards
Jun 15, 1986·Toxicology and Applied Pharmacology·L A DethloffG E Hook
Jun 1, 1987·The Journal of Pathology·I Y Adamson, D H Bowden
Jun 1, 1987·The Journal of Pathology·I Y Adamson, D H Bowden
Jan 1, 1988·General Pharmacology·T E Weaver
Oct 1, 1988·The American Review of Respiratory Disease·F Possmayer
May 1, 1988·Toxicology and Applied Pharmacology·V CastranovaP R Miles
Mar 1, 1988·The American Review of Respiratory Disease·P C RobinsonR J Mason
Jun 1, 1987·Journal of Applied Physiology·B A HolmS Matalon
Dec 1, 1985·Biochemical Society Transactions·R J Richards, R Lewis
Sep 15, 1985·Toxicology and Applied Pharmacology·F M Martin, H P Witschi
Aug 1, 1970·The Journal of Pathology·A G HepplestonJ A Stewart
Aug 15, 1972·Experientia·A G HepplestonI Wyatt
Sep 1, 1983·Environmental Health Perspectives·R J Emerson, G S Davis
Apr 1, 1984·Environmental Health Perspectives·R J Richards, C G Curtis
Feb 1, 1981·Environmental Research·S M Le MesurierA W Lykke
Aug 1, 1981·Journal of Applied Physiology: Respiratory, Environmental and Exercise Physiology·S L YoungG W Brumley
Dec 1, 1966·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·S P Sorokin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.